Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Chemotherapy in Neoadjuvant HR+/HER2- Breast Cancer
NCT07197697Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Oct 2025
- Primary completion
- Nov 2027
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in breast cancer, sponsored by Anhui Provincial Tumor Hospital. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07197697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197697.